Pozen News
Most Popular Pozen Story
New combos of old drugs may be boon to biotech
New York Times scribe Andrew Pollack takes a careful look at the current trend of making new drugs out of combinations of old therapies. Despite reporting one trial failure last week, CombinatoRx is out in the lead on this one. Researchers at the company are systematically running through the possible combinations of 2,000 generic drugs. But …
Read more...Latest Headlines
- December 3, 2008
- September 7, 2007
- August 2, 2007
- July 2, 2007
- December 12, 2006
- August 2, 2006
- August 1, 2006
- June 8, 2006
- April 20, 2006
- November 8, 2005
- October 11, 2005
- August 7, 2005
- August 4, 2005
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
